RT Journal Article
SR Electronic
T1 Underreporting of SARS-CoV-2 infections during the first wave of the 2020 COVID-19 epidemic in Finland - Bayesian inference based on a series of serological surveys
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.15.23285941
DO 10.1101/2023.02.15.23285941
A1 Nieminen, Tuomo A.
A1 Auranen, Kari
A1 Kulathinal, Sangita
A1 Härkänen, Tommi
A1 Melin, Merit
A1 Palmu, Arto A.
A1 Jokinen, Jukka
YR 2023
UL http://medrxiv.org/content/early/2023/02/16/2023.02.15.23285941.abstract
AB In Finland, the first wave of the COVID-19 epidemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) took place from March to June 2020, with the majority of COVID-19 cases diagnosed in the extended capital region. The magnitude and trend in the incidence of COVID-19 is one way to monitor the course of the epidemic. The diagnosed COVID-19 cases are a subset of the infections and therefore the COVID-19 incidence underestimates the SARS-CoV-2 incidence. The likelihood that an individual with SARS-CoV-2 infection is diagnosed with COVID-19 depends on the clinical manifestation as well as the infection testing policy and capacity. These factors may fluctuate over time and the underreporting of infections changes accordingly. Quantifying the extent of underreporting allows the assessment of the true incidence of infection. To obtain information on the incidence of SARS-CoV-2 infection in Finland, a series of serological surveys was initiated in April 2020. We develop a Bayesian inference approach and apply it to data from the serological surveys, registered COVID-19 cases, and external data, to estimate the time-dependent underreporting of SARS-Cov-2 infections during the first wave of the COVID-19 epidemic in Finland. There were 1 to 5 (95% probability) SARS-CoV-2 infections for every COVID-19 case during the first wave of the COVID-19 epidemic in Finland. The underreporting was highest before April when there were 4 to 17 (95% probability) infections for every COVID-19 case. It is likely that between 0.5%–1.0% (50% probability) and no more than 1.5% (95% probability) of the population in the extended capital region were infected with SARS-CoV-2 by the beginning of July 2020.Competing Interest StatementWe report no conflict of interests related to the current work. Finnish Institute for Health and Welfare (THL) conducts Public-Private Partnership with vaccine manufacturers and has received research funding from Sanofi Inc., Pfizer Inc., and GlaxoSmithKline Biologicals SA for studies not related to COVID-19. TAN, MM, AAP and JJ have been investigators in these studies, but they have received no personal remuneration.Funding StatementThis study was funded by the Finnish Institute for Health and Welfare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical review board of Helsinki and Uusimaa Hospital district gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymous data data produced for the purposes of this work are available in the present article. The programming code which implements the statistical methods described, anonymous data included in this article, and an R code example for learning the parameters of the described statistical models, and are available online: github.com/TuomoNieminen/covid19underreporting. Individual level data are not available due to data privacy. More detailed data related to the COVID-19 cases in Finland are available by formal request to the Finnish Social and Health Data Permit Authority Findata. https://github.com/TuomoNieminen/covid19underreporting